236 related articles for article (PubMed ID: 33152120)
21. Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure.
Lotfi R; Moeller P; Schmid M; Schrezenmeier H
Ann Hematol; 2011 Nov; 90(11):1357-9. PubMed ID: 21327404
[No Abstract] [Full Text] [Related]
22. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
25. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
Mokhtar GM; Tantawy AA; El Sherif NH
Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
[TBL] [Abstract][Full Text] [Related]
26. Use of romiplostim for primary immune thrombocytopenia in children.
Escudero Vilaplana V; Aragonés JH; Fernández-Llamazares CM; Bieler CB; Rodríguez SM; Sáez MS
Pediatr Hematol Oncol; 2012 Mar; 29(2):197-205. PubMed ID: 22376020
[TBL] [Abstract][Full Text] [Related]
27. Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
Rosa María RN; Laura RL; Ángeles PB; Laura LB
Platelets; 2020; 31(3):403-406. PubMed ID: 31116059
[TBL] [Abstract][Full Text] [Related]
28. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
29. Rapid blood cell recovery with immunosuppressive therapy combined with romiplostim in a patient with very severe hepatitis-associated aplastic anemia who underwent liver transplantation.
Yoshinari H; Kawahara Y; Niijima H; Oh Y; Hirata Y; Okada N; Sanada Y; Onishi Y; Sakuma Y; Morimoto A
Int J Hematol; 2021 Oct; 114(4):524-527. PubMed ID: 34110619
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
32. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
33. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
35. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
[TBL] [Abstract][Full Text] [Related]
36. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.
Elalfy MS; Abdelmaksoud AA; Eltonbary KY
Ann Hematol; 2011 Nov; 90(11):1341-4. PubMed ID: 21318572
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
38. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag.
Hosokawa K; Yamazaki H; Tanabe M; Imi T; Sugimori N; Nakao S
Leukemia; 2021 Mar; 35(3):906-909. PubMed ID: 32616921
[No Abstract] [Full Text] [Related]
39. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Kuter DJ; Arnold DM; Rodeghiero F; Janssens A; Selleslag D; Bird R; Newland A; Mayer J; Wang K; Olie R
Am J Hematol; 2020 Jun; 95(6):643-651. PubMed ID: 32129511
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
Meletis J; Katsandris A; Raptis SD; Mantzourani M
Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
